The ED50 and ED95 of Intrathecal Isobaric Bupivacaine with Opioids for Cesarean Delivery |
| |
Authors: | Carvalho, Brendan M.B.B.Ch., F.R.C.A. Durbin, Marie M.D. Drover, David R. M.D. Cohen, Sheila E. M.B. Ch.B., F.R.C.A. Ginosar, Yehuda B.Sc., M.B.B.S.
Riley, Edward T. M.D. |
| |
Affiliation: | Carvalho, Brendan M.B.B.Ch., F.R.C.A.*; Durbin, Marie M.D.†; Drover, David R. M.D.*; Cohen, Sheila E. M.B. Ch.B., F.R.C.A.‡; Ginosar, Yehuda B.Sc., M.B.B.S.§; Riley, Edward T. M.D.∥ |
| |
Abstract: | Background: The ideal intrathecal isobaric bupivacaine dose for cesarean delivery anesthesia is uncertain. While small doses (5-9 mg) of bupivacaine may reduce side effects such as hypotension, they potentially increase spinal anesthetic failures. This study determined the ED50 and ED95 of intrathecal isobaric bupivacaine (with adjuvant opioids) for cesarean delivery. Methods: After institutional review board approval and written informed consent were obtained, 48 parturients undergoing elective cesarean delivery under combined spinal-epidural anesthesia were enrolled in this double-blind, randomized, dose-ranging study. Patients received a 5-, 6-, 7-, 8-, 9-, 10-, 11-, or 12-mg intrathecal isobaric bupivacaine dose with 10 [mu]g fentanyl and 200 [mu]g morphine. Overall anesthetic success was recorded when no intraoperative epidural supplement was required during the cesarean delivery. ED50 and ED95 values for overall anesthetic success were determined using a logistic regression model. Results: ED50 and ED95 values for overall anesthetic success were 7.25 and 13.0 mg, respectively. No advantages for low doses could be demonstrated with regard to hypotension, nausea, vomiting, pruritus, or maternal satisfaction, although this study was underpowered to detect significant differences in secondary outcome variables. |
| |
Keywords: | |
|
| 点击此处可从《Anesthesiology》浏览原始摘要信息 |
|